Celebrating Dr. Prithvi Ramtohul: Ramin Tadayoni Award Winner
Oculis Champions the Future of Retinal Research
Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a forefront biopharmaceutical company known for its commitment to advancing treatments for ophthalmic and neuro-ophthalmic diseases, has made a significant announcement regarding the Ramin Tadayoni Award for 2025. This recognition, crafted in alliance with EURETINA, champions new talent in the field of retina research.
A Tribute to Visionary Leaders
The Ramin Tadayoni Award was created to honor the legacy of Professor Ramin Tadayoni, who was not just a leader in retinal science but a valued figure within Oculis. This award aims to uplift the next wave of ophthalmologists by rewarding outstanding postgraduate scholars dedicated to retinal studies.
2025 Award Recipient: A Bright Star
In the current selection, Prithvi Ramtohul, M.D., stands out for his remarkable achievements in retinal imaging and various retinal diseases. He is actively researching the plasticity of neuronal excitability within retinal ganglion cells, pushing the boundaries of existing knowledge in the field.
A Word from EURETINA
Anat Loewenstein, M.D., President of EURETINA, shared heartfelt appreciation towards all applicants, calling their entries “remarkable”. She expressed her joy in awarding Dr. Ramtohul. This accolade serves as both recognition and motivation, aligning with Dr. Ramtohul's goal to delve into the cellular dynamics of conditions such as amblyopia, aiming to develop innovative therapeutic strategies that could significantly elevate patient care.
Oculis Highlights Commitment
Dr. Riad Sherif, CEO of Oculis, extended his congratulations to Dr. Ramtohul, commending both his accomplishments and the ongoing partnership with EURETINA in promoting research excellence. Dr. Sherif emphasized the importance of honoring Professor Tadayoni’s legacy and continuing to foster research that has the potential to change lives.
Dr. Prithvi Ramtohul's Journey
Currently, Dr. Ramtohul is involved with the Retinal Division at Aix-Marseille University Hospital, where he serves as a physician while pursuing his Ph.D. at INSERM-AMU in Marseille, France. His academic journey includes a notable residency in ophthalmology and fellowship training under the guidance of Professor Tadayoni in Paris. Additionally, he has enriched his experience through a fellowship with Professor K. Bailey Freund in New York, focusing on retinal research.
Impactful Contributions
Dr. Ramtohul’s academic portfolio boasts 111 peer-reviewed studies, detailing innovative findings such as new OCT imaging markers and identifying rare retinal diseases. His research exploits multimodal imaging techniques to deepen the understanding of retinal pathophysiology, a vital step forward in enhancing treatment methods. His work continues to garner accolades, including the Gabriel Coscas Award and invitations to numerous prestigious conferences worldwide.
About Oculis and Its Mission
Oculis is dedicated to pushing the boundaries of treatment in ophthalmic conditions and affirms its commitment through an impressive clinical pipeline. Among its key products are OCS-01, a pivotal eye drop aimed at treating diabetic macular edema; Privosegtor (OCS-05), engineered for acute optic neuritis; and Licaminlimab (OCS-02), which aims to personalize approaches in dry eye disease. With headquarters in Switzerland and a dynamic presence in the U.S. and Iceland, Oculis thrives under seasoned leadership and has garnered support from prominent healthcare investors.
Further Information
For additional insights about Oculis and its endeavors, you can explore the company’s official website.
Oculis Contacts
Contact Ms. Sylvia Cheung, CFO for inquiries at sylvia.cheung@oculis.com.
Investor Relations
For investor-related queries, reach out to Corey Davis, Ph.D. at LifeSci Advisors, cdavis@lifesciadvisors.com.
Media Relations
For media inquiries, get in touch with ICR Healthcare: oculis@icrhealthcare.com.
Frequently Asked Questions
What is the Ramin Tadayoni Award?
This award recognizes outstanding postgraduate scholars in retinal research, commemorating the legacy of Professor Ramin Tadayoni.
Who is the 2025 award recipient?
The 2025 award is presented to Dr. Prithvi Ramtohul for his contributions to retinal imaging and diseases.
What are Dr. Ramtohul’s research interests?
Dr. Ramtohul focuses on neuronal excitability in retinal ganglion cells and aims to innovate treatment strategies for retinal conditions.
What does Oculis specialize in?
Oculis specializes in innovative biopharmaceutical treatments for ophthalmic and neuro-ophthalmic diseases.
How can I contact Oculis?
You can reach Oculis through their official email for various inquiries or visit their website for more information.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.